STRUCTURE-ACTIVITY AND STRUCTURE-SIDE-EFFECT RELATIONSHIPS FOR THE QUINOLONE ANTIBACTERIALS

被引:559
作者
DOMAGALA, JM
机构
[1] Department of Chemistry, Parke-Davis Pharmaceutical, Research Division of Warner-Lambert Company, Ann Arbor, MI 48105
关键词
D O I
10.1093/jac/33.4.685
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The fluoroquinolones represent a major class of antibacterials with great therapeutic potential. Over the years, several structure-activity and side-effect relationships have been developed, covering thousands of analogues, in an effort to improve overall antimicrobial efficacy while reducing undesirable side-effects. In this review, the various structural features of the quinolones which govern antibacterial efficacy and influence the side-effect profile are delineated and summarized at the molecular level. Those features which most remarkably enhance antimicrobial effectiveness are: a halogen (F or Cl) at the 8-position which improves oral absorption and activity against anaerobes; an alkylated pyrrolidine or piperazine at C7 which increases serum half-life and potency vs Gram-positive bacteria; and a cyclopropyl group at N1 and an amino substituent at C5, both of which improve overall potency. Some side-effects of the quinolones are class effects, and cannot be modulated by molecular variation. These include gastrointestinal irritation and arthropathy. Several other potential side-effects are directly influenced by structural modification. For example, CNS effects and drug interactions with theophylline and NSAIDs are strongly influenced by the C7 substituent with simple pyrrolidines and piperazines the worst actors. Increasing steric bulk through alkylation ameliorates these effects. Phototoxicity is determined by the nature of the 8-position substituent with halogen causing the greatest photo reaction while hydrogen and methoxy show little light induced toxicity. Genetic toxicity is controlled in additive fashion by the choice of groups at the 1, 7 and 8 positions. From the analysis, those groups which mutually improve efficacy while reducing side-effects are identified. In addition, preclinical models for determining potential side-effects are discussed. © 1994 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:685 / 706
页数:22
相关论文
共 71 条
  • [11] QUINOLONE ANTIBACTERIALS CONTAINING THE NEW 7-[3-(1-AMINOETHYL)-1-PYRROLIDINYL] SIDE-CHAIN - THE EFFECTS OF THE 1-AMINOETHYL MOIETY AND ITS STEREOCHEMICAL CONFIGURATIONS ON POTENCY AND INVIVO EFFICACY
    DOMAGALA, JM
    HAGEN, SE
    JOANNIDES, T
    KIELY, JS
    LABORDE, E
    SCHROEDER, MC
    SESNIE, JA
    SHAPIRO, MA
    SUTO, MJ
    VANDERROEST, S
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (07) : 871 - 882
  • [12] ELSEA SH, 1992, J BIOL CHEM, V267, P13150
  • [13] THE WITHDRAWAL OF TEMAFLOXACIN - ARE THERE IMPLICATIONS FOR OTHER QUINOLONES
    FINCH, RG
    [J]. DRUG SAFETY, 1993, 8 (01) : 9 - 11
  • [14] Foote C. S., 1976, FREE RADICALS BIOLOG, P85, DOI DOI 10.1016/B978-0-12-566502-5.50010-X
  • [15] FORSGREN A, 1989, REV INFECT DIS, V11, pS1382
  • [16] FUHR U, 1993, MOL PHARMACOL, V43, P191
  • [17] INHIBITORY POTENCY OF QUINOLONE ANTIBACTERIAL AGENTS AGAINST CYTOCHROME-P450IA2 ACTIVITY INVIVO AND INVITRO
    FUHR, U
    ANDERS, EM
    MAHR, G
    SORGEL, F
    STAIB, AH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (05) : 942 - 948
  • [18] INHIBITORY EFFECTS OF QUINOLONE ANTIBACTERIAL AGENTS ON EUKARYOTIC TOPOISOMERASES AND RELATED TEST SYSTEMS
    GOOTZ, TD
    BARRETT, JF
    SUTCLIFFE, JA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (01) : 8 - 12
  • [19] QUINOLONE ARTHROPATHY - ACUTE TOXICITY TO IMMATURE ARTICULAR-CARTILAGE
    GOUGH, AW
    KASALI, OB
    SIGLER, RE
    BARAGI, V
    [J]. TOXICOLOGIC PATHOLOGY, 1992, 20 (03) : 436 - 449
  • [20] GRACHECK SJ, 1991, 21ST INT C ANT AG CH